Search results
Results from the WOW.Com Content Network
The anti-TNF-α monoclonal antibody infliximab is a major biological therapy for inflammatory bowel diseaseBiological therapy, the use of medications called biopharmaceuticals or biologics that are tailored to specifically target an immune or genetic mediator of disease, plays a major role in the treatment of inflammatory bowel disease. [1]
Common side effects include infections, acute infusion reactions, and abdominal pain. [23] Infliximab is a chimeric monoclonal antibody biologic. It seems to work by binding to and neutralizing TNF-α, preventing it from interacting with its receptors on the cell. [23] TNF-α is a chemical messenger and a key part of the autoimmune reaction.
Sarcoidosis may resolve without any treatment within a few years. [2] [5] However, some people may have long-term or severe disease. [5] Some symptoms may be improved with the use of anti-inflammatory drugs such as ibuprofen. [8] In cases where the condition causes significant health problems, steroids such as prednisone are indicated. [9]
The World Association of Sarcoidosis and other Granulomatous Disorders, also known as WASOG is an organisation of physicians involved in the diagnosis and treatment of sarcoidosis and related conditions.
reduction of side effects of cardiac surgery: Pidilizumab [40] mab: humanized: PD-1: cancer and infectious diseases Pinatuzumab vedotin [40] mab: humanized: CD22: cancer Pintumomab: mab: mouse: adenocarcinoma antigen: adenocarcinoma (imaging) Placulumab [15] mab: human: TNF: pain and inflammatory diseases Pozelimab [35] Veopoz: mab: human: C5 ...
A TNF inhibitor is a pharmaceutical drug that suppresses the physiologic response to tumor necrosis factor (TNF), which is part of the inflammatory response.TNF is involved in autoimmune and immune-mediated disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriasis, hidradenitis suppurativa and refractory asthma, so TNF inhibitors may be used in their ...
As the drug is delivered to the site of action extremely rapidly with IV injection, there is a risk of overdose if the dose has been calculated incorrectly, and there is an increased risk of side effects if the drug is administered too rapidly. [25]
If this is effective, the dose may gradually be reduced (although many patients need to remain on steroids long-term, frequently leading to side-effects such as diabetes or osteoporosis). Methotrexate , hydroxychloroquine , cyclophosphamide , pentoxifylline , thalidomide and infliximab have been reported to be effective in small studies.